lurasidone / Generic mfg. - LARVOL DELTA

Food for thought: re-emergence of tardive dyskinesia amid nutritional rehabilitation of atypical anorexia nervosa; a case report. (PubMed, J Eat Disord) - "Nutritional rehabilitation likely has an impact on the metabolism of certain antipsychotic medications including lurasidone. More research is needed involving patients recovering from a restrictive eating disorder who are on antipsychotic medications and the frequency of increased side effects, including tardive dyskinesia, with refeeding."

Journal • Anorexia • Bipolar Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Psychiatry

Post-lanosterol inhibition profile based classification of commonly used prescription medications. (PubMed, Transl Psychiatry) - "Using LC-MS/MS we measured 13 post-lanosterol intermediates in control, DHCR7 +/- and DHCR7-/- human dermal fibroblasts exposed to cariprazine, nebivolol, rotigotine, buspirone, lurasidone, fluoxetine, hydroxyzine, amiodarone, spiroxamine, vilazodone and ziprasidone. In addition, DHCR7 +/- fibroblasts responded with greater sterol profile disruptions to all medications, while DHCR7 fibroblasts from patients with Smith-Lemli-Opitz syndrome showed generally a more plateaued response. Knowing the inhibition profile-based classification of medications that have a sterol inhibiting side effect might ultimately translate into safety recommendations during pregnancy and could be critical for new drug development."

Journal • DHCR7

Fine-tuning 5-HT7 receptor selectivity, inverse agonism, and metabolic stability of new (aryloxy)ethyl-piperidines toward antidepressant and pro-cognitive properties. (PubMed, Eur J Med Chem) - "Clinically used antidepressants and second-generation antipsychotic drugs, including vortioxetine and lurasidone, act as potent 5-HT7 receptor antagonists and improve cognitive functions in the patients with mood disorders. In addition, compound 57 reduced 5-HT7 receptor-mediated MMP-9 activity in the mouse hippocampus with efficacy comparable to the reference 5-HT7 receptor antagonist, SB-269970, further suggesting its purported antidepressant-like actions. These findings support the potential therapeutic application of targeting 5-HT7 receptor/MMP-9 signaling pathway for the treatment of affective disorders."

Journal • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry • MMP9

Voluntary Wheel Running Improves Cognitive Deficits and Abnormal Agonistic Behavior Induced by Social Isolation Stress in Mice. (PubMed, Physiol Behav) - "Our results suggest that, while VWR and lurasidone both mitigate some aspects of SI-induced behavioral deficits, they likely act independent or only partially overlapping neurobiological pathways. Thus, VWR may act through broader neuroadaptive processes, potentially involving serotonergic modulation, neurotrophic factors, or stress regulatory circuits."

Journal • Preclinical • CNS Disorders • Cognitive Disorders • Depression • Mood Disorders • Psychiatry

The current nursing care of patients diagnosed with dual diagnosis: a comprehensive literature review. (PubMed, BMC Nurs) - "Nursing care of patients diagnosed with dual diagnosis is most effective when integrated, patient-centred, and combining psychosocial with pharmacological approaches. Therapeutic relationships, consumer engagement, and structured planning support recovery. However, documentation gaps, low participation, and poor aftercare remain barriers needing innovation, policy, and research."

Journal • CNS Disorders • Mood Disorders

Cutaneous Pseudolymphomas of the Scalp Secondary to Lamotrigine. (PubMed, Cureus) - "The patient was switched to lurasidone, leading to complete resolution of the scalp nodules. This case supports lamotrigine-induced cutaneous pseudolymphoma, a rare but reversible condition, and emphasizes the need for clinicians to consider drug-induced pseudolymphoma."

Journal • Bipolar Disorder • CNS Disorders • Hematological Malignancies • Lymphoma • Mood Disorders • Oncology • Psychiatry

A Systematic Literature Review of Economic Evaluation Studies for Schizophrenia (ISPOR-EU 2025) - "SGAs such as olanzapine, paliperidone, and clozapine were frequently associated with improved relapse prevention and reduced inpatient costs, contributing to favorable cost-effectiveness profiles compared to haloperidol or other FGAs. Newer agents, including lurasidone and brexpiprazole, appeared in a limited number of recent studies... This review reinforces the long-term value of schizophrenia interventions, particularly SGAs, and underscores the need for consistent methodological standards. These findings contribute to a more robust evidence base for HTA submissions, inform pricing and reimbursement decisions, and support the development of sustainable, value-based mental health policies."

HEOR • Review • CNS Disorders • Psychiatry • Schizophrenia

Site-selective addition of succinimide motif through nitro-assisted C-H functionalization of (hetero) arenes under rhodium catalysis. (PubMed, Arch Pharm Res) - "Succinimide motifs are recognized as privileged cores in anticonvulsants and antipsychotics such as phensuximide, ethosuximide, and lurasidone. The versatility of the developed protocol is demonstrated through nitro-group reduction, reductive cyclization of the synthesized products, and selective modifications of the succinimide framework. Mechanistic studies, including deuterium-labeling and kinetic isotope effect experiments, helped elucidate a plausible reaction mechanism."

Journal • CNS Disorders

The impact of CYP3A4 rs2242480 on oral lurasidone: A population pharmacokinetic model and exposure-efficacy analysis in Chinese bipolar depression patients. (PubMed, J Affect Disord) - "The pharmacokinetics of lurasidone in patients with bipolar depression are significantly influenced by IBW and the rs2242480 genotype, enabling a practical framework for precision dosing."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry • CYP3A4

Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis. (PubMed, Int Clin Psychopharmacol) - "This study aimed to: (a) systematically review randomized controlled trials (RCTs) evaluating the cognitive effects of third-generation antipsychotics (TGAs: brexpiprazole, cariprazine, lumateperone, and lurasidone) and xanomeline-trospium; and (b) perform a network meta-analysis (NMA) including additional second-generation antipsychotics with potential procognitive effects. A systematic literature search identified eligible RCTs, which were combined with trials on aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone from a previous meta-analysis...In conclusion, selected second and TGAs, including M1/M4 receptor agonists such as xanomeline, may offer promising treatment options for cognitive dysfunction. Further research should personalize pharmacological strategies based on cognitive profiles."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Sigma-1-targeting multimodal compound HBK-15 reverses memory deficits and restores hippocampal plasticity under NMDA hypofunction. (PubMed, Neurotherapeutics) - "We therefore investigated whether HBK-15 engages sigma-1 receptors and restores memory in a mouse model of MK-801-induced impairment...In contrast, vortioxetine and lurasidone showed only limited benefits, highlighting the broader effectiveness of HBK-15...These findings offer experimental evidence that HBK-15 activates sigma-1 receptors to enhance hippocampal plasticity at both synaptic and network levels and to improve memory under NMDA hypofunction. Taken together, our results highlight sigma-1-based strategies as a tractable avenue for developing treatments targeting cognitive symptoms in depression and schizophrenia."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Psychiatry • Schizophrenia

Grading the Evidence- Bipolar Disorder and Schizophrenia (AACAP 2025) - "FDA approval will also be part of the metric in helping to determine recommendations. Multiple studies are available that are funded by the NIH and FDA for psychosis (primarily schizophrenia) that show high levels of evidence, ie, grades 1A and 1B for benefit with tolerable side effects including newer medications such as lurasidone. Other medications have good efficacy but higher side-effect burdens such as clozapine. Finally, some medications have inadequate separation from placebo and are not approved, such as ziprasidone and asenapine... The field of psychopharmacology for bipolar and psychotic disorders has a number of completed controlled trials that contribute to the evidence base. Clinicians can use the GRADE system to recommend medications based on the balance of efficacy vs adverse event burden to obtain symptom control.BRD, PSY, PTA"

Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Pediatrics • Psychiatry • Schizophrenia

Innovation of Spectroscopic Approach for Investigation of Lurasidone in Pharmaceutical Formulations and Spiked Human Plasma. (PubMed, Luminescence) - "The approach was assessed in accordance with ICH specifications. There were no excipient-related interferences during the application of the analyses."

Journal

Identification of N-Debenzisothiazole-Lurasidone as an Enzymatic Degradation Product of Lurasidone. (PubMed, J Anal Toxicol) - "The detection of N-debenzisothiazole-lurasidone in postmortem casework indicates that, where possible, it should be included in toxicology screening methods targeting psychoactive compounds. Until such time that a commercially available reference standard of N-debenzisothiazole-lurasidone is available, the comprehensive accurate mass and mass spectral data of N-debenzisothiazole-lurasidone that are now available enable its inclusion as a "suspect target" in high-resolution-mass-spectrometry screening methods."

Journal

Balancing Mental Health and Breastfeeding: Evaluating the Transfer of Lurasidone Into Human Milk. (PubMed, J Clin Psychiatry) - " The levels of lurasidone observed in all participants' milk samples were exceedingly low. The subsequently low RID is below the 10% threshold for infant safety, suggesting that the transfer of maternal lurasidone into human milk is clinically insignificant and poses minimal risk to a breastfed infant."

Journal • CNS Disorders

Bipolar disorder in children, adolescents and young adults. Part 2. Therapeutic management. Recommendations under the patronage of the Executive Board of the Polish Psychiatric Association, National Consultants in the field of Psychiatry and National Consultants in Child and Adolescent Psychiatry. (PubMed, Psychiatr Pol) - "Lithium, aripiprazole, quetiapine, risperidone, olanzapine, asenapine, ziprasidone are recommended for the treatment of mania and mixed states. For the treatment of depressive episodes in bipolar disorder in children and adolescents, experts recommend lurasidone as monotherapy or olanzapine + fluoxetine as combination therapy. Although long-term treatment is a key aspect of bipolar disorder management in children and adolescents, consistent efficacy data are still lacking. Safety data indicate that the most commonly reported adverse reactions in children and adolescents treated with mood stabilizers are gastrointestinal and neurological adverse reactions, while the use of antipsychotics is mainly associated with weight gain and sedation."

Clinical guideline • Journal • Review • Anesthesia • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A multi-center, randomized, open-label study. (PubMed, World J Psychiatry) - "Initial doses of 40 mg/day and 80 mg/day lurasidone are safe and effective for acute schizophrenia, with no significant increase in AEs-related discontinuation rate at the higher dose."

Clinical • Journal • CNS Disorders • Depression • Mental Retardation • Psychiatry • Schizophrenia

Effect of lurasidone plus sulpiride on treatment efficacy, psychiatric manifestations, and quality of life among patients with schizophrenia. (PubMed, World J Psychiatry) - "The combination of lurasidone and sulpiride can effectively enhance treatment efficacy, alleviate psychiatric symptoms, and improve quality of life in patients with schizophrenia, supporting its broader clinical use."

HEOR • Journal • Anorexia • CNS Disorders • Dental Disorders • Fatigue • Insomnia • Pain • Psychiatry • Schizophrenia • Sleep Disorder • Xerostomia • IL17A • IL6

Transdiagnostic efficacy of lurasidone on depressive symptoms: systematic review and meta-analysis of randomised controlled trials: commentary, Chen et al. (PubMed, Br J Psychiatry) - No abstract available

Journal • Retrospective data • CNS Disorders • Depression • Psychiatry

Glucose dysregulation signals in weight-neutral atypical antipsychotics: A pharmacovigilance-pharmacodynamic evaluation of FAERS data. (PubMed, J Affect Disord) - "Weight-neutral drugs such as ziprasidone, asenapine, lurasidone, and aripiprazole may be associated with glucose dysregulation, underscoring the need for vigilance when switching antipsychotics. This phenomenon might be attributable to their antagonistic effects on 5-HT2C receptors. However, given the exploratory nature of this study, these findings warrant further validation."

Adverse events • Journal • PK/PD data • CNS Disorders

Reactive psychosis to isotretinoin and management with clozapine in an adolescent (ECNP 2025) - "Isotretinoin was stopped and sequential antipsychotics (aripiprazole up to 30 mg/day, risperidone 3 mg/day, lurasidone 37.5 mg/night) were trialled without adequate response...Adjunctive sertraline 200 mg/day and trazodone 50 mg/night were added for residual apathy and sleep dysregulation...Future studies should investigate genetic and developmental risk markers for retinoid-induced psychosis and establish standardised monitoring and intervention guidelines. No conflict of interest"

CNS Disorders • Psychiatry

Antidepressant efficacy of the atypical antipsychotic lurasidone: preliminary findings from a transdiagnostic systematic review and meta-analysis (ECNP 2025) - "Preliminary findings from this meta-analysis support the efficacy of lurasidone in reducing depressive symptoms across a range of psychiatric disorders. Interpretation is limited by the high study heterogeneity, suggesting the need for further high-quality trials with standardised methodologies and transdiagnostic designs to further clarify lurasidone's therapeutic potential beyond diagnostic boundaries. We also emphasise the value of symptom-focused evidence synthesis approaches to inform patient-centered management and to advance precision psychiatry."

Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Pharmacological strategies targeting negative symptoms in schizophrenia (ECNP 2025) - "In a 14-week RCT versus risperidone (n = 460), it achieved a 2.6 point greater reduction on the PANSS Negative subscale (p<0.001) and improved social functioning [4]. Low-dose amisulpride and lurasidone have shown moderate benefits, particularly when negative symptoms are secondary to depression or extrapyramidal effects...Cholinergic modulation with xanomeline–trospium recently showed significant reductions in both positive and negative symptoms in a phase II trial (n = 182), suggesting a novel non-dopaminergic approach. Antidepressant augmentation (primarily SSRIs and mirtazapine) produced modest additional benefits, though heterogeneity across studies tempers confidence [5]... Emerging pharmacotherapies targeting dopamine D3 receptors, serotonergic modulation and glutamatergic pathways offer promising avenues for alleviating negative symptoms in schizophrenia. Cariprazine and roluperidone have demonstrated the most robust RCT evidence, memantine is a viable adjunct..."

CNS Disorders • Depression • Psychiatry • Schizophrenia

A case report: acute lithium toxicity triggered by parsley juice consumption (ECNP 2025) - "Case Presentation A 46-year-old male patient with Bipolar Mood Disorder, under regular outpatient follow-up for six months and treated with lithium (1500 mg/day), divalproex sodium (1500 mg/day), lurasidone (80 mg/day), and propranolol (40 mg/day) for the past four months, had been in remission for three months with a lithium level of 0.82 mEq/L. Patients may consider herbal or dietary supplements harmless, but these substances can have potent biological effects and interact with prescribed medications. Clinicians should maintain a high level of suspicion, particularly when managing medications like lithium, which are sensitive to changes in renal function and hydration status."

Case report • Clinical • Bipolar Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Psychiatry

Use of lurasidone in a depressive episode of an adolescent patient with bipolar 2 disorder: a case report (ECNP 2025) - "The patient, who used sertraline, olanzapine and risperidone in his psychiatric follow-ups, was admitted to our psychiatric inpatient unit due to the fact that he did not benefit from the treatment in outpatient follow-ups and the risk of suicide. The patient was diagnosed with bipolar 2 disorder during his hospitalization and his treatment was gradually adjusted as risperidone 3 mg/day, quetiapine 600 mg/day, clonazepam 6 mg/day... Lurasidone is classified under the group of dopamine-serotonin antagonists in neuroscience-based nomenclature. Its potent 5-HT7 antagonism on serotonin receptors distinguishes it from other antipsychotics and makes it effective in the treatment of bipolar depression, while its relatively potent 5-HT1a agonism also contributes to this effect. [3] Lithium and quetiapine are recommended as first-line treatments for bipolar depression [4], while current algorithms include lurasidone as the first choice for the treatment of bipolar depression in..."

Case report • Clinical • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Psychiatry • Suicidal Ideation